Appointed
Dominic Rodrigues
President
PVCT ·
PROVECTUS BIOPHARMACEUTICALS, INC.
appointed Dominic Rodrigues as the Company’s President effective April 16, 2024.
Ready 8-Ks
35
Latest filing
June 30, 2026, 7:37 PM ET
Top materiality
0.80
Event mix
other_material ×18 · other ×10 · debt ×4
Sentiment
2 pos · 0 neg · 33 neu
Executive change
recent →
Recent 8-K filings for PVCT
Highest-materiality recent filing
Provectus Biopharmaceuticals Names Dominic Rodrigues Principal Executive Officer; Bruce Horowitz Resigns
- Bruce Horowitz resigned as COO and Director on March 25, 2024, and entered a termination agreement with a total payment of up to $750,000.
- The termination agreement includes an initial $250,000 payment and a second payment of $258,000 if paid before June 30, 2024, otherwise $500,000.
-
Board approved conversion of $542,500 in accrued directors' fees into 189,554 shares of Series D-1 Preferred Stock.
-
Provectus shareholders elect directors, approve reverse stock split authorization
Directors elected: Webster Bailey, John Lacey III, Ed Pershing, Dominic Rodrigues.
-
Provectus Biopharmaceuticals annual meeting update; no specific financial data in filing
Filing states a presentation will be given at the 2026 annual meeting; no financial results or material events disclosed.
-
Provectus to hold 2026 annual meeting at planned new headquarters, Perkins Place in Knoxville
Annual meeting set for June 18, 2026 at 4:00 p.m. ET at Perkins Place, 525 Portland Street, Knoxville.
-
Provectus extends automatic conversion date for Series D and D-1 preferred stock to Dec 2028
Automatic conversion date for Series D and D-1 preferred stock extended from June 20, 2026 to December 31, 2028.
-
Stockholders elected all four director nominees: Bailey, Lacey, Pershing, Rodrigues, with >200M votes for each.
-
Provectus provides broad business update at annual meeting; no specific results disclosed
Company presented on clinical development, regulatory, discovery, manufacturing, IP, and corporate development.
-
Provectus BioPharma appoints CBIZ as new auditor following Marcum acquisition
Marcum LLP resigned as independent auditor on April 15, 2025, due to its acquisition by CBIZ.
-
Provectus Biopharma approves up to $10M convertible loan financing for drug development
Board approved 2025 Term Sheet to arrange up to $10M unsecured convertible loan in tranches.
-
Provectus assigns exclusive ophthalmic license to majority-owned subsidiary VisiRose
Assigns exclusive license with University of Miami for photodynamic antimicrobial therapy in ophthalmology to VisiRose, effective Dec 9, 2024.
-
Provectus launches VisiRose subsidiary to develop RB PDAT for eye infections
VisiRose formed as Delaware subsidiary to commercialize rose bengal sodium for ophthalmology, targeting infectious keratitis.
-
CEO Ed Pershing receives 25,470,215 options (grant date value $3,081,896) at $0.2862 exercise price.
-
Provectus references Q4 2024 investor update; no specific details in filing
Filing announces Fourth Quarter 2024 Investor Update presentation slides as Exhibit 99.1.
-
Provectus converts $2.13M in director fees to Series D-1 Preferred shares
Converted $2,131,838.75 in accrued directors’ fees into 744,878 shares of Series D-1 Preferred at $2.862 per share.
-
Provectus announces up to $10M convertible loan financing at 8% interest
Board approved term sheet for up to $10M unsecured convertible loan (2024 Financing) from multiple investors.
-
Provectus redeems 11.4M Series D shares for 1.14M Series D-1 shares; authorized share counts amended
VP and President Dominic Rodrigues forfeits 11,416,262 Series D Preferred shares for 1,141,626 Series D-1 shares.
-
All six proposals passed at June 20, 2024 annual meeting; directors elected with >96% votes cast.
-
Update covers clinical development, regulatory, drug discovery, manufacturing, IP, and business development.
-
Provectus appoints Pershing as CEO and Rodrigues as President effective April 16
Ed Pershing appointed CEO effective April 16; will continue as Board Chairman; salary $240,000/year.
-
Provectus licenses University of Miami's rose bengal PDAT for eye infections; will form spinout
Exclusive worldwide license for photodynamic antimicrobial therapy (PDAT) using rose bengal sodium to treat bacterial, fungal, and acanthamoeba keratitis.
-
Bruce Horowitz resigned as COO and Director on March 25, 2024, and entered a termination agreement with a total payment of up to $750,000.
-
Provectus holds conference call and furnishes slide deck; no specific details in filing
Company hosted conference call on Feb 22, 2024 at 3:00 PM EST to provide updates.
-
Provectus Biopharmaceuticals to host conference call on Feb 22, 2024 for company updates
Conference call scheduled for February 22, 2024 at 3:00 p.m. EST to discuss company updates.
-
Provectus Biopharma stockholders authorize reverse stock split and reduce authorized shares
Reverse stock split approved (321.7M for) at ratio of 1:10 to 1:50, Board to determine exact ratio.
-
Provectus Biopharma provides annual meeting update, slides attached
Update covers clinical development, regulatory, drug discovery, manufacturing, IP, business and corporate development.
-
Provectus adds social media channels for investor updates; discontinues email newsletter
Will use Substack, Twitter, and LinkedIn for material disclosures.
-
Provectus outlines 2023 regulatory path for PV-10 in rare in-transit melanoma, updates pipeline
Plans regulatory pathway for PV-10 monotherapy to treat rare in-transit melanoma; cites 56% CR in 121 patients.
-
Board decided not to undertake the reverse stock split and authorized share reduction approved at 2022 Annual Meeting.
-
Provectus Biopharmaceuticals approves up to $5M convertible note financing
Board approved term sheet for up to $5M in convertible notes; proceeds fund drug discovery and G&A.
-
Provectus shareholders approve reverse stock split, elect directors at annual meeting
All five director nominees elected: Bailey, Horowitz, Lacey, Pershing, Rodrigues; 102.4M broker non-votes.
-
Annual stockholders meeting held on June 22, 2022.
-
Provectus seeks approval for 1-for-10 to 1-for-50 reverse stock split at June 22 annual meeting
Filed preliminary proxy; meeting scheduled for June 22, 2022; record date April 25, 2022.
-
Provectus eliminates Series B Preferred Stock, increases Series D-1 authorized shares
Filed Certificate of Elimination for Series B Convertible Preferred Stock; all shares converted to common on Aug 25, 2021.
-
Provectus reports fully diluted shares of 528.7M as of Sep 7, 2021, down from 563.9M in 2017
Fully diluted shares outstanding as of Sep 7, 2021: 528,667,356 vs 563,911,848 in 2017.
-
Provectus Biopharma approves up to $5M convertible loan; CFO invests $200K
Board approved financing term sheet for up to $5,000,000 unsecured convertible loan.
Executive changes
Appointed
Ed Pershing
Chief Executive Officer
PVCT ·
PROVECTUS BIOPHARMACEUTICALS, INC.
appointed Ed Pershing as the Company’s Chief Executive Officer effective April 16, 2024.
Appointed
Dominic Rodrigues
Chief Operations Consultant
PVCT ·
PROVECTUS BIOPHARMACEUTICALS, INC.
the Board retained Dominic Rodrigues as the Company’s chief operations consultant.
Departed
Bruce Horowitz
Chief Operating Officer
PVCT ·
PROVECTUS BIOPHARMACEUTICALS, INC.
On March 25, 2024, Bruce Horowitz resigned from the Board of Directors (the “Board”) of Provectus Biopharmaceuticals, Inc. (the “Company”) and as the Company’s Chief Operating Officer.
Departed
Bruce Horowitz
Director
PVCT ·
PROVECTUS BIOPHARMACEUTICALS, INC.
On March 25, 2024, Bruce Horowitz resigned from the Board of Directors (the “Board”) of Provectus Biopharmaceuticals, Inc. (the “Company”) and as the Company’s Chief Operating Officer.
Materiality & sentiment trend
Max materiality 0.80 · Median 0.50 · Most common event other_material